Pacira Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative non-opioid pain management solutions
The company is dedicated to improving patient outcomes by offering products that mitigate post-surgical pain while minimizing the reliance on traditional opioid medications. Pacira's lead product is designed for effective local anesthetic delivery, aiming to enhance recovery experiences for patients undergoing various surgical procedures. Through its commitment to research and development, Pacira seeks to advance medical practices in pain management and promote safer alternatives for both healthcare providers and patients.
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
Consider PACIRA BIOSCIENCES INC as a top value stock. NASDAQ:PCRX shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQPCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions.
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQPCRX) and certain of its officers.
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQPCRX) and certain of its officers.
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQPCRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers or acquirers of securities of Pacira BioSciences, Inc. (NASDAQPCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”). Pacira is a pharmaceutical company.
